|
- Agios
At Agios, personal connections count Our ability to work together with patient communities, healthcare professionals, partners and colleagues – and honor each of their perspectives – powers our continued success in creating groundbreaking therapies for the patients who need them
- Pipeline – Agios
A pipeline of possibility Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need
- About Us - Agios
Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to pioneering new investigational medicines for the treatment of rare diseases Learn more about our deep history in cellular metabolism and the path we’ve taken since 2008
- Medical – Agios
Agios supports Investigator Sponsored Trials (ISTs), which are independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations and medical treatment in alignment with our clinical and nonclinical areas of interest
- Our Medicines – Agios
At Agios, people living with rare diseases are at the center of everything we do and every decision we make Their needs, concerns, input and collaboration are essential to fulfilling our mission: to make a meaningful difference in patients’ lives and fundamentally change the way rare diseases are treated
- Contact – Agios
For medical information queries, please contact us at the phone numbers or email addresses below Report an adverse event or product complaint anytime
- Agios ASH 2025 Data Room – Agios
Agios is presenting new preclinical and clinical data on mitapivat, the company’s first-in-class pyruvate kinase (PK) activator, along with research from two Agios-supported advisory councils at ASH 2025 Select presentations and publications at ASH 2025 include: Two poster presentations on results from the ENERGIZE-T Phase 3 trial of mitapivat in adults with transfusion-dependent alpha- or
- History – Agios
While Agios has evolved significantly since our founding, our commitment to making a positive impact for patients, employees, communities and the world remains unchanged As we create the future of Agios together, we are building on our core values and pioneering leadership in cellular metabolism to advance our work on behalf of people with rare diseases
|
|
|